[
  {
    "ts": null,
    "headline": "Investing in the Age of Longevity: Silver Economy Stocks in Focus",
    "summary": "AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.",
    "url": "https://finnhub.io/api/news?id=b3582e7207a3ecfdf3bf3f6a605b1ba2b447312272ad44481659168aa2062524",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756746660,
      "headline": "Investing in the Age of Longevity: Silver Economy Stocks in Focus",
      "id": 136604097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie, Amgen, Stryker and Dexcom are tapping into the booming silver economy with new therapies, tech and acquisitions aimed at aging populations.",
      "url": "https://finnhub.io/api/news?id=b3582e7207a3ecfdf3bf3f6a605b1ba2b447312272ad44481659168aa2062524"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Golden Cross Signals Strength: How to Play the Stock",
    "summary": "Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.",
    "url": "https://finnhub.io/api/news?id=766b7bbe3cfaf3f14842b487bb761254e5a7e1e7add1dbf89f118fba2d7c5ac2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756745940,
      "headline": "Pfizer's Golden Cross Signals Strength: How to Play the Stock",
      "id": 136604057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.",
      "url": "https://finnhub.io/api/news?id=766b7bbe3cfaf3f14842b487bb761254e5a7e1e7add1dbf89f118fba2d7c5ac2"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Stock Underperforming the S&P 500?",
    "summary": "AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=5bdf2370c1fb5608d89481531b9715489661ccd98dd4c416273e234e46291295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756737569,
      "headline": "Is AbbVie Stock Underperforming the S&P 500?",
      "id": 136604099,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=5bdf2370c1fb5608d89481531b9715489661ccd98dd4c416273e234e46291295"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work",
    "summary": "Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company No. 7 up from No. 8 last year.",
    "url": "https://finnhub.io/api/news?id=a180c5f220702257df4e3707a0675311e8c21ded3b2434cdab367b579ad7d7c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756692000,
      "headline": "AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work",
      "id": 136596139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Great Place To Work®, the global authority on workplace culture, has selected AbbVie for the 2025 Best Workplaces in Asia™ List, ranking the company No. 7 up from No. 8 last year.",
      "url": "https://finnhub.io/api/news?id=a180c5f220702257df4e3707a0675311e8c21ded3b2434cdab367b579ad7d7c9"
    }
  }
]